흡입 항생제 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the inhaled antibiotics market size was valued at USD 1.76 billion in 2025 and is estimated to grow from USD 1.92 billion in 2026 to reach USD 2.93 billion by 2031, at a CAGR of 8.88% during the forecast period (2026-2031).

Global Inhaled Antibiotics Market Trends and Insights

Growing Cystic Fibrosis and Bronchiectasis Burden

Cystic fibrosis and non-CF bronchiectasis remain key demand drivers for the inhaled antibiotics market. Cystic fibrosis affects 70,000 patients globally, while the reported incidence of non-CF bronchiectasis ranges from 8.2 to 52 cases per 100,000 people, depending on diagnostic practices and region. Increased use of high-resolution computed tomography identifies previously undiagnosed cases, particularly in Asia and Latin America, where diagnostic capacity is expanding. This trend broadens the patient pool requiring specialist assessment and long-term respiratory management.

Zambon's Phase 3 PROMIS-I study enrolled 377 patients with non-CF bronchiectasis. The study reported a 39% reduction in annual pulmonary exacerbations and a 59% reduction in severe exacerbations with inhaled colistimethate sodium delivered through the I-neb system. These results provided large-scale, double-blind, placebo-controlled evidence for this patient group. European Respiratory Society and British Thoracic Society guidance links antibiotic stewardship with inhaled therapy for suitable bronchiectasis patients, supporting its use in recurrent infections and chronic colonization.

Rising Drug-Resistant Pulmonary Infections and Earlier Detection

Antimicrobial resistance is increasing interest in antibiotics that deliver treatment directly to the lungs. The WHO 2025 surveillance report covered cases reported by 110 countries from 2016 through 2023 and highlighted continued resistance concerns for carbapenem-resistant P. aeruginosa. This organism is a common Gram-negative pathogen in hospital-acquired and ventilator-associated pneumonia. Earlier microbiological identification enables clinicians to align treatment with the causative organism and the pulmonary site of infection.

A 2025 network meta-analysis reported that nebulized tobramycin improved clinical recovery in non-severe ventilator-associated pneumonia, with a risk ratio of 1.7 and a 95% confidence interval of 1.1 to 2.7 compared with systemic alternatives. WHO AWaRe guidance supports appropriate antibiotic selection and use across health systems. Consequently, hospital formulary committees may evaluate parenteral and inhaled regimens more closely for chronic pulmonary infections. While long-term inhaled antibiotic use may contribute to resistance selection, the available evidence does not indicate a change in current treatment guidance.

Treatment Cost, Reimbursement Restrictions, and Limited Evidence

High treatment costs limited access to branded inhaled antibiotics outside the United States. Annual ARIKAYCE therapy costs reached the high tens of thousands of dollars. National health systems and public hospital formularies applied stringent economic thresholds and restricted coverage to narrow, label-approved populations. Consequently, some clinically eligible patients did not meet reimbursement requirements. A 2025 Chinese analysis found inhaled tobramycin inhalation solution economically dominant over nebulized colistimethate sodium for bronchiectasis patients. Net benefit per patient ranged from CNY 14,776 to CNY 47,361 (USD 2,045 to USD 6,554). The analysis used generic-priced tobramycin rather than branded specialty medicines. Health technology assessment processes delayed access by 12 to 24 months in some countries, while limited routine-use evidence in non-refractory infections increased formulary caution, particularly in Europe and APAC.

Other drivers and restraints analyzed in the detailed report include:

1. Improved Nebulizer and Dry-Powder Delivery Technologies
2. Expanded Use in Refractory NTM Lung Disease and Lower Systemic Exposure
3. Bronchospasm, Airway Irritation, and Treatment Burden

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Aerosol or metered-dose inhaler formulations accounted for 38.56% of the product type segment in 2025. This share reflected the extensive nebulizer infrastructure across hospitals and specialty care settings. Established agents, including tobramycin and colistimethate sodium, require substantial drug loads that nebulizers can deliver without strong inspiratory effort or breath-hold coordination. These characteristics remain relevant for patients with severely reduced lung function.

The dry-powder segment is forecast to grow at a CAGR of 10.55% through 2031. A 2025 pediatric study found that dry-powder tobramycin delivered through the Cyclops device was well tolerated among cystic fibrosis patients aged 6 to 18 years. The study reported no significant decline in FEV1, mild adverse events, and lower systemic exposure than nebulized delivery. These findings support the demand for portable long-term treatment options. Spray formulations and nebulized solutions remain relevant in acute and intensive care settings, where high drug delivery volumes and rapid treatment take priority over portability. Pressurized metered-dose inhalers have a narrower role because each puff generally delivers less than 1 mg of drug. This dose is unsuitable for antibiotic regimens requiring several hundred milligrams. The Inhaled Antibiotics Market product mix will continue to reflect clinical settings and dose requirements.

Aminoglycosides held 58.67% of the drug class segment in 2025. Tobramycin inhalation solution has a substantial prescription base in cystic fibrosis and is available in several strengths. Ritedose received FDA approval for a generic tobramycin inhalation solution in October 2025, expanding generic options for eligible patients. Aminoglycosides remain important across cystic fibrosis, bronchiectasis, and NTM lung disease.

A 2025 systematic review compared amikacin liposome, tobramycin, aztreonam lysine, levofloxacin, and colistin. It found that all five agents reduced sputum bacterial density among relevant cystic fibrosis and bronchiectasis populations. The review found no significant difference in culture conversion among the agents. When efficacy is comparable, device design and formulation may become more important, favoring products that reduce administration burden or address specific clinical needs.

Complete Report Scope:

• By Product Type
  • Aerosol or Metered-Dose Inhaler
  • Dry-Powder Formulation
  • Spray Formulation
  • Nebulized Antibiotic Solution
• By Drug Class
  • Aminoglycosides
  • Fluoroquinolones
  • Monobactams
  • Polymyxins
  • Macrolides
  • Other Drug Classes
• By Indication
  • Cystic Fibrosis
  • Pneumonia
  • Bronchitis
  • Chronic Obstructive Pulmonary Disease With Bacterial Infection
  • Asthma
  • Other Respiratory Infections
• By End User
  • Hospitals
  • Specialty Clinics
  • Respiratory Care Centers
  • Ambulatory Care Centers
  • Homecare Providers
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 38.78% of the geographic segment in 2025, supported by a broad base of approved therapies and established specialty prescribing. FDA orphan-drug designations strengthened the development and approval pathway for rare respiratory conditions, supporting the Inhaled Antibiotics Market in the United States. The region also has an established generic tobramycin and aztreonam treatment base. Insmed reported USD 133.1 million in U.S. ARIKAYCE revenue in the first half of 2026, compared with USD 133.0 million in the first half of 2025. Canada contributes through registry-linked cystic fibrosis prescribing, while Mexico has a smaller contribution due to limited specialty infrastructure and access. The July 2026 ARIKAYCE sNDA could expand the eligible patient population if approved.

Europe has advanced respiratory centers, although access varies across countries. Germany, the United Kingdom, France, Italy, and Spain lead regional prescribing volumes. ARIKAYCE Liposomal 590 mg Nebulizer Dispersion is approved in Europe for MAC lung disease in non-CF bronchiectasis. While the European Medicines Agency provides a centralized authorization process, national reimbursement negotiations and payer decisions influence market access. Germany's AMNOG process has supported faster specialist access than the United Kingdom's NICE review process, contributing to differences in prescription volumes. European respiratory institutions also develop treatment guidance for bronchiectasis and NTM. Savara's MOLBREEVI marketing authorization application is expected to receive a CHMP decision in the first quarter of 2027, indicating continued pipeline activity in inhaled pulmonary therapies.

Asia-Pacific is forecast to grow at a CAGR of 12.72% through 2031. China and India offer significant volume opportunities as specialist care and high-resolution computed tomography use expand, improving the identification of non-CF bronchiectasis cases. WHO surveillance reported high P. aeruginosa resistance in hospital-acquired infections across the region. Japan remains a mature, high-value market, supported by PMDA approval for ARIKAYCE and strong NTM awareness.

1. Altan Pharma Limited
2. Aradigm
3. Bayer
4. Chiesi Farmaceutici
5. Cipla
6. Gilead Sciences
7. Insmed
8. Joincare Pharmaceutical Group Industry Co., Ltd.
9. Kindeva Drug Delivery
10. Lupin
11. Novartis
12. PARI Pharma GmbH
13. Pfizer
14. Pharmaxis Ltd.
15. Pulmatrix, Inc.
16. Savara Inc.
17. Spexis AG
18. Teva Pharmaceutical Industries
19. Viatris
20. Viatris Specialty LLC
21. Zambon S.p.A.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Burden of Cystic Fibrosis and Bronchiectasis
  • 4.2.2 Increasing Prevalence of Drug-Resistant Pulmonary Infections
  • 4.2.3 Expansion of Inhaled Antibiotic Use in Refractory Nontuberculous Mycobacterial Lung Disease
  • 4.2.4 Advances in Nebulizer and Dry-Powder Delivery Technologies
  • 4.2.5 Earlier Microbiological Detection Enabling Targeted Pulmonary Therapy
  • 4.2.6 Reduced Systemic Exposure Through Lung-Localized Antibiotic Delivery
• 4.3 Market Restraints
  • 4.3.1 Bronchospasm and Local Airway Irritation
  • 4.3.2 High Treatment Cost and Reimbursement Restrictions
  • 4.3.3 Device-Dependent Adherence and Treatment-Burden Challenges
  • 4.3.4 Limited Evidence for Routine Use in Non-Refractory Infections
• 4.4 Value/Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Product Type
  • 5.1.1 Aerosol or Metered-Dose Inhaler
  • 5.1.2 Dry-Powder Formulation
  • 5.1.3 Spray Formulation
  • 5.1.4 Nebulized Antibiotic Solution
• 5.2 By Drug Class
  • 5.2.1 Aminoglycosides
  • 5.2.2 Fluoroquinolones
  • 5.2.3 Monobactams
  • 5.2.4 Polymyxins
  • 5.2.5 Macrolides
  • 5.2.6 Other Drug Classes
• 5.3 By Indication
  • 5.3.1 Cystic Fibrosis
  • 5.3.2 Pneumonia
  • 5.3.3 Bronchitis
  • 5.3.4 Chronic Obstructive Pulmonary Disease With Bacterial Infection
  • 5.3.5 Asthma
  • 5.3.6 Other Respiratory Infections
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Specialty Clinics
  • 5.4.3 Respiratory Care Centers
  • 5.4.4 Ambulatory Care Centers
  • 5.4.5 Homecare Providers
  • 5.4.6 Others
• 5.5 By Distribution Channel
  • 5.5.1 Hospital Pharmacies
  • 5.5.2 Retail Pharmacies
  • 5.5.3 Online Pharmacies
  • 5.5.4 Specialty Pharmacies
  • 5.5.5 Others
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Altan Pharma Limited
  • 6.3.2 Aradigm Corporation
  • 6.3.3 Bayer AG
  • 6.3.4 Chiesi Farmaceutici S.p.A.
  • 6.3.5 Cipla Limited
  • 6.3.6 Gilead Sciences, Inc.
  • 6.3.7 Insmed Incorporated
  • 6.3.8 Joincare Pharmaceutical Group Industry Co., Ltd.
  • 6.3.9 Kindeva Drug Delivery L.P.
  • 6.3.10 Lupin Limited
  • 6.3.11 Novartis AG
  • 6.3.12 PARI Pharma GmbH
  • 6.3.13 Pfizer Inc.
  • 6.3.14 Pharmaxis Ltd.
  • 6.3.15 Pulmatrix, Inc.
  • 6.3.16 Savara Inc.
  • 6.3.17 Spexis AG
  • 6.3.18 Teva Pharmaceutical Industries Ltd.
  • 6.3.19 Viatris Inc.
  • 6.3.20 Viatris Specialty LLC
  • 6.3.21 Zambon S.p.A.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment